Status:
COMPLETED
A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Brief Summary
The primary objective of this NIS is to assess the clinical benefit subjects derive from taking seroquel XR, using the CGI-CB. The secondary objective is to assess the effectiveness,safety and tolerab...
Eligibility Criteria
Inclusion
- Diagnosed as Schizophrenia according to DSM-IV-TR criteria
- Patients who are taking Seroquel XR no longer than 1 month
- Patients who get antipsychotics monotherapy at least 1 week before enroll in this study
Exclusion
- First episode, drug naive schizophrenic subjects.
- Meeting the criteria for any other (than schizophrenia) DSM-IV Axis I diagnosis,concomitant organic mental disorder or mental retardation that in the opinion of the Principal Investigator may interfere with study conduct or interpretation.
- Known lack of response to clozapine or treatment with clozapine within 4 weeks prior to enrollment.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
1494 Patients enrolled
Trial Details
Trial ID
NCT00922090
Start Date
July 1 2009
End Date
January 1 2010
Last Update
March 12 2010
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Busan, South Korea
2
Research Site
Daegu, South Korea
3
Research Site
Goyang, South Korea
4
Research Site
Gwangju, South Korea